MGNX logo

MacroGenics Inc. (MGNX)

$2.05

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MGNX

Market cap

$131013339

EPS

-0.82

P/E ratio

--

Price to sales

1.42

Dividend yield

--

Beta

1.335349

Price on MGNX

Previous close

$2.17

Today's open

$2.13

Day's range

$2.02 - $2.18

52 week range

$1.32 - $5.08

Profile about MGNX

CEO

Eric Risser

Employees

293

Headquarters

Rockville, MD

Exchange

Nasdaq Global Select

Shares outstanding

63908946

Issue type

Common Stock

MGNX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MGNX

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients First patient dosed with MGC030 in Phase 1 study Strengthened Board with addition of two new independent directors with expertise in oncology drug discovery and development Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028 ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.

news source

GlobeNewsWire • Nov 12, 2026

news preview

MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to earnings of $0.27 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management team will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference (New York, NY). MacroGenics' President and CEO, Eric Risser, will participate in a fireside chat on Wednesday, November 11, at 10:00 am ET.

news source

GlobeNewsWire • Nov 5, 2026

news preview

MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D.

ROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointments of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D.

news source

GlobeNewsWire • Nov 3, 2026

news preview

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

news source

GlobeNewsWire • Oct 26, 2026

news preview

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.

news source

GlobeNewsWire • Oct 23, 2026

news preview

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

ROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1 study of MGC030, a first-in-class antibody-drug conjugate (ADC) directed against an undisclosed target, in patients with advanced solid tumors. “MGC030 demonstrated encouraging antitumor activity in multiple preclinical models, and we look forward to advancing this product candidate through the Phase 1 study.

news source

GlobeNewsWire • Oct 15, 2026

news preview

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Oct 9, 2026

news preview

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

news source

Seeking Alpha • Oct 7, 2026

news preview

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.

news source

GlobeNewsWire • Sep 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MacroGenics Inc.

Open an M1 investment account to buy and sell MacroGenics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MGNX on M1